Mirum Pharmaceuticals, INC Form 4 insider transactions

Eric Bjerkholt, CHIEF FINANCIAL OFFICER of Mirum Pharmaceuticals, Inc., sold 6,001 shares of common stock on August 11, 2026 for $99.90 per share.

Christopher Peetz, CHIEF EXECUTIVE OFFICER and a Director of Mirum Pharmaceuticals, Inc., sold 20,000 shares of common stock on August 10, 2026.

Jolanda Howe, SVP, GLOBAL CONTROLLER of Mirum Pharmaceuticals, Inc., sold 1,840 shares of common stock on August 3, 2026 for $105.29 per share.

Mirum Pharmaceuticals CEO Christopher Peetz reported transactions involving company stock, including the acquisition of shares and the sale of a significant number of shares under a Rule 10b5-1 trading plan.

Mirum Pharmaceuticals' Chief Financial Officer, Eric Bjerkholt, has sold a total of 4,722 shares of common stock under a pre-arranged trading plan.

Jolanda Howe, SVP Global Controller at Mirum Pharmaceuticals, reported a sale of 2,721 common stock shares on July 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe, SVP Global Controller at Mirum Pharmaceuticals, reported a sale of 2,594 shares of common stock on June 17, 2026, executed under a Rule 10b5-1 trading plan.

Director Timothy P. Walbert received an equity grant of stock options and restricted stock units from Mirum Pharmaceuticals.

Director Lon Cardon received an equity grant of stock options and restricted stock units from Mirum Pharmaceuticals.

Director Saira Ramasastry received an equity grant of stock options and restricted stock units from Mirum Pharmaceuticals.

Director William Fairey received an equity grant of stock options and deferred stock units from Mirum Pharmaceuticals.

Director Laura Brege received an equity grant of stock options and deferred stock units from Mirum Pharmaceuticals.

Director Patrick J. Heron was granted stock options and deferred stock units by Mirum Pharmaceuticals.

Director Laurent Fischer was granted stock options and deferred stock units by Mirum Pharmaceuticals on June 15, 2026.

Director Michael G. Grey received an equity grant of stock options and restricted stock units from Mirum Pharmaceuticals.

Mirum Pharmaceuticals CFO Eric Bjerkholt sold 5,000 shares and exercised 2,393 stock options under a pre-arranged 10b5-1 trading plan.

Mirum Pharmaceuticals President and COO Peter Radovich acquired 16,988 shares of common stock via vested stock options at a price of $19.19 per share.

Mirum Pharmaceuticals CEO Christopher Peetz exercised 30,000 stock options and sold a portion of the resulting shares under a Rule 10b5-1 trading plan.

Mirum Pharmaceuticals Director Timothy Walbert acquired 3,977 shares of common stock through the vesting of restricted stock units.

Mirum Pharmaceuticals Director Lon Cardon acquired 3,977 shares of common stock through the vesting of restricted stock units.

Director Saira Ramasastry exercised restricted stock units and sold 3,977 shares of Mirum Pharmaceuticals common stock.

Mirum Pharmaceuticals director Laurent Fischer acquired 3,977 shares of common stock through the vesting of restricted stock units.

Mirum Pharmaceuticals director Saira Ramasastry exercised 2,000 stock options and sold the resulting shares under a 10b5-1 plan.

Mirum Pharmaceuticals director Saira Ramasastry exercised 2,000 stock options and subsequently sold the shares.

Mirum Pharmaceuticals' CFO, Eric Bjerkholt, acquired shares from vested performance restricted stock units and subsequently sold a portion to cover tax withholding obligations.

Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, sold 7,287 shares of common stock to cover tax obligations following the vesting of 13,334 performance restricted stock units.

Mirum Pharmaceuticals Director Saira Ramasastry exercised stock options and immediately sold the resulting common stock under a pre-arranged 10b5-1 plan.

Mirum Pharmaceuticals' President and COO, Peter Radovich, reported the vesting of performance restricted stock units and subsequent sale of shares to cover tax obligations.

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, reported the vesting of performance restricted stock units and a subsequent sale of shares to cover tax obligations.

Mirum Pharmaceuticals CEO Christopher Peetz reported the vesting of performance restricted stock units and subsequent sale of shares to cover tax obligations.